CAPhO 2026 Evolving Treatment Goals in Polycythemia Vera: Beyond Hematocrit Control

FORUS Therapeutic Inc. Sponsored Symposium

Management of polycythemia vera (PV) continues to evolve as treatment goals expand beyond hematocrit control and symptom management toward long-term disease modification. This symposium will explore the evolving therapeutic landscape and emerging clinical evidence in PV, including findings from prospective studies of novel long-acting immunomodulatory therapies such as ropeginterferon alfa-2b.